3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Carcinoma, Hepatocellular
20
Nasopharyngeal Carcinoma
12
Triple Negative Breast Neoplasms
11
Esophageal Neoplasms
11
Stomach Neoplasms
10
Esophageal Squamous Cell Carcinoma
10
Sarcoma
7
Squamous Cell Carcinoma of Head and Neck
6
Lung Neoplasms
6
Uterine Cervical Neoplasms
5
Melanoma
5
Hodgkin Disease
5
Recurrence
4
Colorectal Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Advanced Gastric Cancer
3
Respiratory Tract Diseases
2
Rectal Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Nasopharyngeal Neoplasms
2
Metastatic Gastric Adenocarcinoma
2
Lymphoma, Extranodal NK-T-Cell
2
Lung Diseases
2
Interventions
sintilimab
1
pembrolizumab
1
lenvatinib
1
camrelizumab
1
Sugammadex
1
Neoadjuvant Therapy
1
Irinotecan
1
Immune Checkpoint Inhibitors
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Granulocyte Colony-Stimulating Factor
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Hepatoblastoma
×
camrelizumab
×
Clear all
NCT05322187
2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3
Unknown
15 enrolled